Legend Biotech
LEGN
15.25
-0.85
-5.28%
Legend Biotech
US · LEGN
#2374 by market cap
Listed 2020
15.25
-0.85
-5.28%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
Recent news
-
Rating change
RBC Capital Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $58Market Newswire · 2026/9/11
-
Barclays Maintains Legend Biotech(LEGN.US) With Buy Rating, Cuts Target Price to $61Market Newswire · 2026/11/11
-
Rating change
Barclays Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $68Market Newswire · 2026/11/6
-
Rating change
UBS Maintains Legend Biotech(LEGN.US) With Hold Rating, Maintains Target Price $28Market Newswire · 2026/8/14
-
Rating change
A Quick Look at Today's Ratings for Legend Biotech(LEGN.US), With a Forecast Between $24 to $65Market Newswire · 2026/8/12
-
Rating change
Piper Sandler Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $64Market Newswire · 2026/11/5
-
Rating change
UBS Maintains Legend Biotech(LEGN.US) With Hold Rating, Cuts Target Price to $24Market Newswire · 2026/10/2
-
Rating change
Analysts Offer Insights on Healthcare Companies: Immunic (IMUX), Legend Biotech (LEGN) and Sagimet Biosciences, Inc. Class A (SGMT)TipRanks · 2026/8/12
-
Rating change
UBS Maintains Legend Biotech(LEGN.US) With Hold Rating, Maintains Target Price $24Market Newswire · 2026/10/28
-
Rating change
Barclays Maintains Legend Biotech(LEGN.US) With Buy Rating, Cuts Target Price to $68Market Newswire · 2026/10/13
-
Rating change
Barclays Maintains Legend Biotech(LEGN.US) With Buy Rating, Cuts Target Price to $74Market Newswire · 2026/9/11
-
Rating change
Analysts Have Conflicting Sentiments on These Healthcare Companies: Intuitive Surgical (ISRG), Legend Biotech (LEGN) and Mineralys Therapeutics, Inc. (MLYS)TipRanks · 2026/8/12
-
Rating change
RBC Capital Maintains Legend Biotech(LEGN.US) With Buy Rating, Cuts Target Price to $56Market Newswire · 2026/10/8
-
Rating change
A Quick Look at Today's Ratings for Legend Biotech(LEGN.US), With a Forecast Between $24 to $48Market Newswire · 2026/8/13
-
A Quick Look at Today's Ratings for Legend Biotech(LEGN.US), With a Forecast Between $25 to $65Market Newswire · 2026/11/12
-
Evercore Initiates Legend Biotech(LEGN.US) With Hold Rating, Announces Target Price $20Market Newswire · 2026/11/14
-
Rating change
Goldman Sachs Maintains Legend Biotech(LEGN.US) With Buy Rating, Cuts Target Price to $38.09Market Newswire · 2026/10/14
-
Rating change
J.P. Morgan Maintains Legend Biotech(LEGN.US) With Hold Rating, Cuts Target Price to $33Market Newswire · 2026/10/9
-
H.C. Wainwright Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $65Market Newswire · 2026/11/11
-
Morgan Stanley Maintains Legend Biotech(LEGN.US) With Buy Rating, Cuts Target Price to $43Market Newswire · 2026/11/12
-
Rating change
J.P. Morgan Downgrades Legend Biotech(LEGN.US) to Hold Rating, Cuts Target Price to $35Market Newswire · 2026/7/13
-
Rating change
RBC Capital Maintains Legend Biotech(LEGN.US) With Buy Rating, Cuts Target Price to $59Market Newswire · 2026/7/27
-
H.C. Wainwright Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $65Market Newswire · 2026/10/30
-
Rating change
Goldman Sachs Maintains Legend Biotech(LEGN.US) With Buy Rating, Cuts Target Price to $40.5Market Newswire · 2026/7/16
-
Core product sales performance reaffirmed; when will Legend Biotech (LEGN.US) reverse the "strong in the short term, weak in the medium term" stock price structure?Zhitong Finance · 2026/10/15
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 20:02:40 · For reference only, not investment advice and not tailored to your situation.
Legend Biotech discussion 0 comments